NYSEAMERICAN:STXS Stereotaxis (STXS) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free STXS Stock Alerts $2.30 -0.05 (-2.13%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.27▼$2.3950-Day Range N/A52-Week Range$1.33▼$3.29Volume236,795 shsAverage Volume306,430 shsMarket Capitalization$188.90 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Stereotaxis alerts: Email Address Stereotaxis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside95.7% Upside$4.50 Price TargetShort InterestHealthy1.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.23) to ($0.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.24 out of 5 stars 3.5 Analyst's Opinion Consensus RatingStereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStereotaxis has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.34% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Stereotaxis has recently increased by 0.59%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldStereotaxis does not currently pay a dividend.Dividend GrowthStereotaxis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STXS. Previous Next 1.9 News and Social Media Coverage News SentimentStereotaxis has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Stereotaxis this week, compared to 1 article on an average week.Search Interest2 people have searched for STXS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows8 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stereotaxis insiders have not sold or bought any company stock.Percentage Held by Insiders18.52% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stereotaxis are expected to grow in the coming year, from ($0.23) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stereotaxis is -8.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stereotaxis is -8.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStereotaxis has a P/B Ratio of 11.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Stereotaxis Stock (NYSEAMERICAN:STXS)Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.Read More STXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STXS Stock News HeadlinesApril 22, 2024 | globenewswire.comStereotaxis to Report First Quarter 2024 Financial Results on May 13, 2024April 19, 2024 | investorplace.com3 Penny Stocks That Could Make a Big Comeback by the End of Q2April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? April 17, 2024 | barrons.comStereotaxis Inc.April 10, 2024 | investorplace.com7 Penny Stocks That Could 5X by the End of 2024March 19, 2024 | markets.businessinsider.comStereotaxis Set for Breakout Growth: Buy Rating Affirmed Amidst Regulatory Advances and Robust FinancialsMarch 17, 2024 | investorplace.comLow-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck WithMarch 9, 2024 | seekingalpha.comMajor Regulatory Approvals Coming For Stereotaxis In The Next 10 MonthsApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? March 6, 2024 | seekingalpha.comStereotaxis, Inc. (STXS) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | bizjournals.comSt. Louis public company projects 'breakout growth' as revenue falls, loss widensMarch 5, 2024 | finance.yahoo.comStereotaxis, Inc. (AMEX:STXS) Q4 2023 Earnings Call TranscriptMarch 4, 2024 | benzinga.comRecap: Stereotaxis Q4 EarningsMarch 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Stereotaxis (STXS), LifeMD (LFMD)March 4, 2024 | globenewswire.comStereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United StatesMarch 4, 2024 | globenewswire.comStereotaxis Reports 2023 Full Year Financial ResultsMarch 3, 2024 | msn.comStereotaxis Q4 2023 Earnings PreviewMarch 1, 2024 | benzinga.comEarnings Preview For StereotaxisFebruary 23, 2024 | markets.businessinsider.comLake Street Keeps Their Buy Rating on Stereotaxis (STXS)February 23, 2024 | finanznachrichten.deStereotaxis, Inc.: Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic TechnologyFebruary 22, 2024 | finance.yahoo.comIntermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic TechnologyFebruary 22, 2024 | globenewswire.comIntermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic TechnologyFebruary 20, 2024 | finance.yahoo.comStereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024February 20, 2024 | globenewswire.comStereotaxis to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024February 18, 2024 | morningstar.comStereotaxis Inc STXSJanuary 11, 2024 | nasdaq.comRoth MKM Initiates Coverage of Stereotaxis (STXS) with Buy RecommendationJanuary 8, 2024 | finanznachrichten.deStereotaxis, Inc.: Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation CatheterSee More Headlines Receive STXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNYSEAMERICAN:STXS CUSIPN/A CIKN/A Webwww.stereotaxis.com Phone(314) 678-6100Fax314-678-6159Employees122Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+91.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,710,000.00 Net Margins-77.37% Pretax Margin-77.37% Return on Equity-103.37% Return on Assets-44.67% Debt Debt-to-Equity RatioN/A Current Ratio2.51 Quick Ratio1.88 Sales & Book Value Annual Sales$26.77 million Price / Sales7.21 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book11.75Miscellaneous Outstanding Shares82,130,000Free Float66,919,000Market Cap$193.01 million OptionableNot Optionable Beta1.34 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. David Leo Fischel C.A.I.A. (Age 37)C.F.A., C.P.A., M.B.A., CEO & Chairman Comp: $62.2kMs. Kimberly R. Peery (Age 55)CFO & Secretary Comp: $251.84kMr. Keith GallowayVice President of OperationsMs. Laura Spencer GarthGeneral Counsel & SecretaryMr. Guy JudkowskiEquity Portfolio ManagerKey CompetitorsSemler ScientificNASDAQ:SMLREdap TmsNASDAQ:EDAPElectromedNYSE:ELMDOutset MedicalNASDAQ:OMAxoGenNASDAQ:AXGNView All CompetitorsInsiders & InstitutionsGSG Advisors LLCBought 26,500 shares on 4/11/2024Ownership: 0.032%Essex Investment Management Co. LLCSold 133,430 shares on 2/8/2024Ownership: 1.453%Independent Advisor AllianceBought 68,500 shares on 2/8/2024Ownership: 0.210%Kovack Advisors Inc.Bought 32,493 shares on 2/2/2024Ownership: 0.277%Investors Research CorpBought 35,950 shares on 1/30/2024Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions STXS Stock Analysis - Frequently Asked Questions Should I buy or sell Stereotaxis stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STXS shares. View STXS analyst ratings or view top-rated stocks. What is Stereotaxis' stock price target for 2024? 2 analysts have issued twelve-month price objectives for Stereotaxis' stock. Their STXS share price targets range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 95.7% from the stock's current price. View analysts price targets for STXS or view top-rated stocks among Wall Street analysts. How have STXS shares performed in 2024? Stereotaxis' stock was trading at $2.87 at the beginning of 2024. Since then, STXS stock has decreased by 19.9% and is now trading at $2.30. View the best growth stocks for 2024 here. How were Stereotaxis' earnings last quarter? Stereotaxis, Inc. (NYSEAMERICAN:STXS) released its quarterly earnings data on Monday, March, 4th. The company reported ($0.07) EPS for the quarter, hitting analysts' consensus estimates of ($0.07). The business had revenue of $4.57 million for the quarter, compared to analysts' expectations of $7.55 million. Stereotaxis had a negative net margin of 77.37% and a negative trailing twelve-month return on equity of 103.37%. What guidance has Stereotaxis issued on next quarter's earnings? Stereotaxis updated its first quarter 2024 earnings guidance on Monday, March, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.0 million-$7.0 million, compared to the consensus revenue estimate of $6.7 million. Who are Stereotaxis' major shareholders? Stereotaxis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include GSG Advisors LLC (0.03%). View institutional ownership trends. How do I buy shares of Stereotaxis? Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:STXS) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stereotaxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
